- Home
- ANIX vs SPRO Comparison
ANIX vs SPRO Comparison
Compare ANIX & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- SPRO
- Stock Information
- Founded
- ANIX 1982
- SPRO 2013
- Country
- ANIX United States
- SPRO United States
- Employees
- ANIX N/A
- SPRO N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- ANIX Health Care
- SPRO Health Care
- Exchange
- ANIX Nasdaq
- SPRO Nasdaq
- Market Cap
- ANIX 101.4M
- SPRO 66.5M
- IPO Year
- ANIX 1987
- SPRO 2017
- Fundamental
- Price
- ANIX $3.08
- SPRO $1.28
- Analyst Decision
- ANIX Strong Buy
- SPRO Strong Buy
- Analyst Count
- ANIX 2
- SPRO 3
- Target Price
- ANIX $8.50
- SPRO $7.00
- AVG Volume (30 Days)
- ANIX 42.0K
- SPRO 140.0K
- Earning Date
- ANIX 10-29-2024
- SPRO 11-11-2024
- Dividend Yield
- ANIX N/A
- SPRO N/A
- EPS Growth
- ANIX N/A
- SPRO N/A
- EPS
- ANIX N/A
- SPRO 0.33
- Revenue
- ANIX N/A
- SPRO $118,459,000.00
- Revenue This Year
- ANIX N/A
- SPRO N/A
- Revenue Next Year
- ANIX N/A
- SPRO N/A
- P/E Ratio
- ANIX N/A
- SPRO $3.93
- Revenue Growth
- ANIX N/A
- SPRO 118.43
- 52 Week Low
- ANIX $2.15
- SPRO $0.99
- 52 Week High
- ANIX $5.13
- SPRO $1.89
- Technical
- Relative Strength Index (RSI)
- ANIX 41.08
- SPRO 49.32
- Support Level
- ANIX $2.95
- SPRO $1.20
- Resistance Level
- ANIX $3.11
- SPRO $1.34
- Average True Range (ATR)
- ANIX 0.12
- SPRO 0.05
- MACD
- ANIX -0.01
- SPRO 0.00
- Stochastic Oscillator
- ANIX 19.35
- SPRO 56.25
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.